Skip to main content

9 Result(s)

within Carlos Taxonera Remove this filter

and

  1. No Access

    Article

    Recommendations for the detection of latent tuberculosis infection in patients with immune-mediated inflammatory diseases candidates for anti-TNF therapy may not be applicable in all settings

    Carlos Taxonera, David Olivares, Cristina Alba in Rheumatology International (2022)

  2. Article

    Open Access

    Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients

    Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence...

    Marisa Iborra, Natalia García-Morales, Saoia Rubio… in Scientific Reports (2020)

    Download PDF (1568 KB) View Article

  3. No Access

    Article

    Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patie...

    María Chaparro, Manuel Barreiro-de Acosta, Ana Echarri… in Digestive Diseases and Sciences (2019)

  4. No Access

    Article

    Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis

    Histological remission represents a target distinct from endoscopic healing in ulcerative colitis (UC) and seems a better predictor of clinical outcomes.

    J. Ignacio Fernández-Blanco, Guillermo Fernández-Díaz… in Digestive Diseases and Sciences (2018)

  5. No Access

    Article

    Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

    The impact of prior anti-TNF use on “real-life” outcomes of adalimumab therapy in ulcerative colitis (UC) is not well known.

    Carlos Taxonera, Eva Iglesias, Fernando Muñoz… in Digestive Diseases and Sciences (2017)

  6. No Access

    Article

    Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

    The outcomes of infliximab dose escalation in ulcerative colitis (UC) have not been well evaluated.

    Carlos Taxonera, Manuel Barreiro-de Acosta, Marta Calvo… in Digestive Diseases and Sciences (2015)

  7. Article

    Open Access

    CD209 in inflammatory bowel disease: a case-control study in the Spanish population

    The etiology of Ulcerative Colitis (UC) and Crohn's Disease (CD), considered together as Inflammatory Bowel Diseases (IBD), involves environmental and genetic factors. Although some genes are already known, th...

    Concepción Núñez, Javier Oliver, Juan Luis Mendoza… in BMC Medical Genetics (2007)

    Download PDF (183 KB) View Article

  8. No Access

    Article

    Crohn’s Disease

    Crohn’s disease is a debilitating and expensive disease that is growing in incidence in both develo** and developed countries. While conventional therapies, such as corticosteroids and immunosuppressants, co...

    Dr Julián Panés, Fernando Gomollón, Carlos Taxonera, Joaquin Hinojosa… in Drugs (2007)

  9. No Access

    Article

    Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility

    The great amount of nitric oxide (NO) produced by the inducible isoform of NO synthase (iNOS) exerts deleterious effects, and iNOS expression is raised in the colonic mucosa of inflammatory bowel disease (IBD)...

    M. Carmen Martín, Alfonso Martinez, J. Luis Mendoza, Carlos Taxonera… in Immunogenetics (2007)